American Century Companies Inc. Purchases 95,066 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

American Century Companies Inc. raised its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP by 124.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 171,590 shares of the biotechnology company's stock after purchasing an additional 95,066 shares during the quarter. American Century Companies Inc. owned 0.12% of Aurinia Pharmaceuticals worth $1,541,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. SBI Securities Co. Ltd. bought a new stake in Aurinia Pharmaceuticals during the fourth quarter valued at about $25,000. Blue Trust Inc. grew its stake in shares of Aurinia Pharmaceuticals by 3,041.4% during the 4th quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company's stock valued at $57,000 after acquiring an additional 6,174 shares during the period. Virtu Financial LLC purchased a new stake in Aurinia Pharmaceuticals in the 4th quarter worth approximately $96,000. Cibc World Markets Corp bought a new stake in Aurinia Pharmaceuticals during the 4th quarter worth approximately $113,000. Finally, FMR LLC lifted its holdings in Aurinia Pharmaceuticals by 44.8% during the third quarter. FMR LLC now owns 12,673 shares of the biotechnology company's stock valued at $93,000 after purchasing an additional 3,919 shares in the last quarter. 36.83% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday, March 27th.

Remove Ads

Insider Activity at Aurinia Pharmaceuticals

In other news, insider Greg Keenan sold 8,305 shares of the business's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $8.23, for a total value of $68,350.15. Following the sale, the insider now directly owns 153,484 shares in the company, valued at $1,263,173.32. The trade was a 5.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Joseph M. Miller sold 61,859 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $494,872.00. Following the completion of the transaction, the chief financial officer now directly owns 633,515 shares of the company's stock, valued at approximately $5,068,120. The trade was a 8.90 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 343,898 shares of company stock valued at $2,753,094. Insiders own 4.30% of the company's stock.

Aurinia Pharmaceuticals Price Performance

Shares of Aurinia Pharmaceuticals stock traded up $0.05 during trading on Tuesday, reaching $7.78. 118,428 shares of the stock traded hands, compared to its average volume of 1,352,078. Aurinia Pharmaceuticals Inc. has a 52-week low of $4.71 and a 52-week high of $10.67. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. The business has a fifty day simple moving average of $8.00 and a two-hundred day simple moving average of $8.10. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of -51.92 and a beta of 1.20.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.